Related Experiment Video
Updated: Jan 2, 2026
A Genetically Engineered Mouse Model of Sporadic Colorectal Cancer
Published on: July 6, 2017
Immunogenomics of Colorectal Tumors: Facts and Hypotheses on an Evolving Saga
Irene Catalano1, Elena Grassi2, Andrea Bertotti1
1Department of Oncology, University of Torino, 10060 Candiolo, Torino, Italy; Candiolo Cancer Institute - FPO IRCCS, 10060 Candiolo, Torino, Italy.
Abstract:
Immunotherapy with immune checkpoint inhibitors is an approved treatment option for a subpopulation of patients with colorectal cancers that display microsatellite instability. However, not all individuals within this subgroup respond to immunotherapy, and molecular biomarkers for effective patient stratification are still lacking. In this opinion article, we provide an overview of the different biological parameters that contribute to rendering colorectal cancers with microsatellite instability potentially sensitive to immunotherapy. We critically discuss the reasons why such parameters have limited predictive value and the implications therein. We also consider that a more informed knowledge of response determinants in this tumor subtype could help understand the mechanisms of immunotherapy resistance in microsatellite stable tumors. We conclude that the dynamic nature of the interactions between cancer and immune cells complicates conventional biomarker development and argue that a new generation of adaptive metrics, borrowed from evolutionary genetics, may improve the effectiveness and reliability of clinical decision making.
Insights
Microsatellite instability in colorectal cancer shows immunotherapy promise, but patient selection remains challenging. New evolutionary genetics approaches may enhance treatment decisions for these cancers.
Area of Science:
- Oncology
- Immunology
- Genetics
Background:
- Immunotherapy using immune checkpoint inhibitors is approved for a subset of colorectal cancers with microsatellite instability.
- However, not all patients in this subgroup respond, and effective biomarkers for patient stratification are needed.
Purpose of the Study:
- To review biological factors influencing immunotherapy sensitivity in microsatellite instability-high colorectal cancers.
- To discuss limitations of current biomarkers and their predictive value.
- To explore how understanding response in this subtype can inform immunotherapy resistance mechanisms in microsatellite-stable tumors.
Main Methods:
- Literature review and critical discussion of existing research on biomarkers for immunotherapy response in colorectal cancer.
- Analysis of biological parameters contributing to immunotherapy sensitivity.
- Consideration of evolutionary genetics principles for biomarker development.
Main Results:
- Current biological parameters have limited predictive value for immunotherapy response in microsatellite instability-high colorectal cancers.
- Understanding response determinants could elucidate resistance mechanisms in microsatellite-stable tumors.
Conclusions:
- The dynamic interplay between cancer and immune cells complicates traditional biomarker development.
- Adaptive metrics from evolutionary genetics may offer improved clinical decision-making for immunotherapy in colorectal cancer.
More Related Videos
06:05Author Spotlight: Multiplex Immunofluorescence Combined with Spatial Image Analysis for the Clinical and Biological Assessment of the Tumor Microenvironment
Published on: June 2, 2023
06:52Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres
Published on: July 22, 2020